Leukemia Physician at MD Anderson. Research in AML, CML, other leukemias if it's the right genotype. Views expressed here are my own.
Joined April 2017
- Tweets153
- Following294
- Followers794
- Likes109
Pinned Tweet
Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature
nature.com/articles/s41586-0… @MDAndersonNews
Ghayas Issa retweeted
Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNews).
cancerletter.com/trials-and-…
Ghayas Issa retweeted
"Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," says Dr. Ghayas Issa.
@US_FDA has approved revumenib for some patients with relapsed or refractory acute leukemia: brnw.ch/21wOL2U @GhayasIssa #EndCancer
ALT "The recent FDA approval of revumenib is a major step forward." Ghayas Issa, M.D. Physician & Researcher
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
Ghayas Issa retweeted
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration
@GhayasIssa @MDAndersonNews
The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration
@GhayasIssa @MDAndersonNews
Ghayas Issa retweeted
Menin Inhibition With Revumenib for KMT2A-Rearranged
Relapsed or Refractory Acute #Leukemia (AUGMENT-101): brnw.ch/21wM2Yh #leusm
Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval
ascopubs.org/doi/10.1200/JCO…
Ghayas Issa retweeted
How long do you wait for leukemia fusion RT-PCR, FISH, cytogenetics? Bedside CRISPR-based detection of PML::RARA and BCR::ABL1 fusions as a point of care test, even on a dried blood spot, from #RahulVedula and @ColemanLindsley @DanaFarber #HemeNeoDivision ashpublications.org/blood/ar…
A pleasure to do this on differentiation syndrome with Eytan and Courtney. A thread 🧵
ashpublications.org/blood/ar…
Ghayas Issa retweeted
Menin inhibitors seek to debut as newest targeted therapy for leukaemia bit.ly/3xsRP99
Find out how small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias in this news article
Ghayas Issa retweeted
👉👉Delighted to present results of an investigator-initiated trial of Pirto + Ven + Obin as firstline Rx of pts with #CLL at @EHA_Hematology #EHA2024
A thread 🧵
Asciminib frontline!
Presented at #ASCO24:
ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons. nej.md/4bNNr3c
ALT The cumulative incidence of major molecular response for asciminib and imatinib (imatinib full analysis set).
Nice! Congrats @DavidSeoMD!! Forgive you for missing eclipse events :)
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24:
vimeo.com/932607668/63addff7…
@MDAndersonNews
Ghayas Issa retweeted
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24:
vimeo.com/932607668/63addff7…
@MDAndersonNews
Just published with the #AACR24 presentation, by @DavidSeoMD—
Randomized Placebo-Controlled, Biomarker-stratified Phase 1b #Microbiome Modulation in #Melanoma: Impact of Antibiotic Pre-conditioning.
bit.ly/4cIDANr
@CSpencerPhD @JenWargoMD @MDAndersonNews
Wonderful editorial by Dr Bernt on Barajas et al showing the latest addition to the “club”. Eytan and I have been brewing this trial for a while and it’s finally about to open: menin inhibition for the HOX-high club (including UBTF-TD based on this work)
classic.clinicaltrials.gov/c…
Ghayas Issa retweeted
Menin inhibitors continue to show tremendous promise in AML w/ encouraging clinical activity as single agents and now in comb. w/ HMA’s + Ven in R/R AML w/ NPM1 or KMT2Ar. Great presentation by @GhayasIssa on SAVE trial. Hopeful these agents will make a huge impact in AML. #ASH23
Ghayas Issa retweeted
Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML @GhayasIssa @MDAndersonNews @ASH_Hematology #ASH23 #ASH2023 #leusm onclive.com/view/revumenib-c…
